Loading…
Concord Medical Services Holdings Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CCM.
▼ -85.4% over 5Y.
today you would have $116.50▼ -88.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.86 | $5.38 | $11.00 | $16.40 | |
| P/S | 2.2x | 1.1x | 1.8x | 2.7x | 4.5x |
| EPS | — | -$70.50 | -$68.10 | -$112.20 | |
| Profit margin | -67.83% | -20.15% | -80.28% | -55.39% | -103.72% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AKTXAkari Therapeutics Plc | $10.70 | — | 1.0x | — | -140.09% | $20.83M |
| NEUPNeuphoria Therapeutics Inc. | $3.76 | — | 0.7x | — | -62.90% | $20.32M |
| CTSOCytosorbents Corp | $0.34 | — | — | — | -336.21% | $21.09M |
| LFWDLifeward Ltd. | $7.46 |
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Company description provided by Yahoo Finance.
| — |
| 3.3x |
| — |
| -225.65% |
| $21.13M |
| COCPCocrystal Pharma, Inc. | $1.10 | — | 14.5x | — | -311.68% | $21.19M |
| LGVNLongeveron Inc. | $6.72 | — | 20.5x | — | -203.61% | $21.42M |